Endocyte Announces First Quarter 2011 Earnings Conference Call

/ Source: GlobeNewswire

WEST LAFAYETTE, Ind., April 28, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the company will host a conference call on Thursday, May 5, 2011, at 4:30 PM Eastern Daylight Time to discuss its first quarter 2011 financial results and provide an operational update.

Investors and the general public are invited to listen to a live webcast of the call in the Investor Relations section of the Company's website at or by dialing 877-845-0711 (US/Canada) or 760-298-5081 (International).

A replay of the call will be available beginning at 6:30 PM ET on May 5, 2011, until Midnight ET on May 12, 2011. To access the replay, please dial 800-642-1687 (US/Canada) or 706-645-9291 (International) and reference the conference ID 63259213. Additionally, the webcast will be recorded and available on the Company's website for two weeks following the call.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

During the course of this presentation, we will make forward-looking statements regarding future events and our future performance. The words "believe", "anticipate", "expect", "estimate", "intend", "plan", "may", "will" and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. Please see the sections entitled "Risk Factors" and "Information Regarding Forward-Looking Statements" in our prospectus recently filed with the SEC for a more detailed description of the risks and uncertainties to which we are subject and for additional information regarding forward-looking statements.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200 stephanie@sternir.com Martina Schwarzkopf, Ph.D., Russo Partners (212) 845-4292 martina.schwarzkopf@russopartnersllc.com Tony Russo, Ph. D., Russo Partners (212) 845 4251 tony.russo@russopartnersllc.com